Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair restoration. RCH-01 is an autologous cell therapy utilizing dermal sheath cup (DSC) cells isolated from the hair follicle to treat androgenetic alopecia. RCS-01 is an autologous cell therapy utilizing non-bulbar dermal sheath (NBDS) cells, a type of fibroblast cell isolated from the hair follicle to repair and regenerate tissue. RCT-01 provides a source of collagen expressing cells to the site of injury, addressing the underlying cause of tendinosis. It has also developed an injection device, DermaPrecise, which improves the administration of its cell therapy products and certain other injectables.


TSXV:RP - Post by User

Bullboard Posts
Comment by lv_426on Feb 13, 2020 1:28pm
46 Views
Post# 30686867

RE:RE:RE:RE:RE:RE:Dermal Injector Roll-out

RE:RE:RE:RE:RE:RE:Dermal Injector Roll-out
Inv3strr wrote:

Not in this case.... we already know that AMI is making the RCI injectors and AMI is a company that specializes in CE marks and medical devices... When AMI started making the RCI they were thinking about how to make it so they could  get a CE mark... they wouldnt make it with the wrong plastic or with materials that would be rejected for a CE mark. They buildt it with the CE mark goal from the beginning. Thats what AMi does. 

CE mark is most important testing right now and they can do that without the commercial grade devices.

The End user testing will happen later,,.. but thats for the marketing. So they can say that it is 99.8% accurate with dosage compared to 78% accuracy with normal needles. Or that it reduces need for anesthetic by 99% of injections. Or that it enters the skin layer at a 100% accuracy rate. Or that it reduces infections by 99% compared to normal needles that have a 78% infectino rate.... Thats a different kinda testing than what they ar doing now...

I worked on a project with a CE mark for my university a couple years ago... the most important thing was that a device doesnt catch fire or electric shocks.. also  that it has zero types of certain chemicals that are actually really hard to eliminate in materials. Like metal has lead and plastic has impurities. 

AMI knows all of that .... they used the right materials from day 1 or they wouldn't be making medical devices.... also they make med devices not just for replicel they make other medical devices  for themselves and other companies too. 





Again I dont doubt what your saying, you seem to have firsthand knowledge of attaining a CE mark. My point is that replicel release info that is misleading to the average investor. Misleading in the respect of not giving specifics so we have to make assumptions
Bullboard Posts